English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduJohns Hopkins Carey Business School Senior Lecturer Supriya Munshaw – an expert in the commercialization of early-stage technologies, especially in the life science and medical device industries – offers her insights into the FDA’s rationale for approving the Alzheimer’s drug aducanumab, the price set by Biogen, the future of FDA leadership, and other related topics, in this Q&A.
Tag: FDA advisory panel
Rutgers Professor Appointed to FDA’s Tobacco Products Scientific Advisory Committee
Cristine Delnevo, director of the Rutgers Center for Tobacco Studies and a professor of Health Behavior, Society, and Policy at the Rutgers School of Public Health, has been appointed to serve on the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee (TPSAC)
Us Against Alzheimer’s advocacy group must reveal financial conflict of interest to FDA, says Dr. Leslie Norins of Alzheimer’s Germ Quest
Alzheimer’s advocacy groups taint their credibility by not revealing conflicts when they lobby FDA for drug approval
Alzheimer’s Association again endorses Biogen drug despite mystery data analysis and financial conflict of interest, says Dr. Leslie Norins of Alzheimer’s Germ Quest
Although an expert FDA panel voted ten to one to withhold approval for a Biogen anti-Alzheimer’s drug candidate, the Alzheimer’s Association endorsed the compound. Serious questions have been raised about why, including conflict of interest.